Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease

Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01801722

Acronym

NT-proBNP

Enrollment

Registered

2013-03-01

Start date

2008-04-30

Completion date

2008-06-30

Last updated

2018-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Heart Failure, Chronic Obstructive Pulmonary Disease

Brief summary

The aim of the present study was to evaluate if the analysis of NT-proBNP might be used as an initial step for the diagnosis of chronic heart failure in patients with COPD in primary health care, and to select patients for a further examination by echocardiography.

Detailed description

Patients with a confirmed diagnosis of COPD were examined regarding chronic heart failure. 1. An interview regarding symptoms: breathlessness, orthopnoea, night cough, nocturia, walking distance. 2. Physical examination: weight and height, heart and lung auscultation, blood pressure measurement after 5 minutes' rest in the sitting position and the presence of peripheral oedema. 3. Electrocardiography. 4. Natriuretic peptide- NT-proBNP (Immulite 2500, Siemens Healthcare Diagnostics AB Sweden). 5. Patients with the NT-proBNP level of \> 1200 pg/ml were referred for echocardiography to assess left ventricular function.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

65 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients aged 65 years and older with the following diagnosis codes according to International Statistical Classification of Diseases and Related Health Problems - Tenth Revision:J44 (COPD) and J41, J42 (chronic bronchitis) registered during the period 1 January 2008-16 April 2008 according to the electronic patient record.

Exclusion criteria

* Impaired cognitive function and/or anticipated difficulties in carrying out spirometry due to immobility, * psychiatric disorders or terminal illness.

Design outcomes

Primary

Measure	Time frame	Description
Percentage of patients with elevated NT-proBNP.	3 months	NT-proBNP has taken only once in each patient without follow up follow up. Three months was a period when we collected data from all participants.

Secondary

Measure	Time frame	Description
Percentage of patients with abnormal left ventricular function assessed by echocardiography. Association between elevated NT-proBNP and symptoms, signs and electrocardiography.	3 months	Echocardiography was performed once in each referred patient. Three months was a period of data collection.

Countries

Sweden

Outcome results